Hansa Biopharma: 115m EUR Licensing Deal in Europe - Redeye
Redeye comments on the licensing deal with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA. It significantly improves the balance sheet for the cost of some long-term value creation.
ANNONS
Redeye comments on the licensing deal with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA. It significantly improves the balance sheet for the cost of some long-term value creation.
